Recruiting

Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study

To determine if nifedipine and enalapril will have better blood pressure control in the postpartum setting compared to nifedipine and labetalol.

ClinicalTrials.gov IDNCT07363343

PhaseNA

Enrollment200

SponsorThe Cleveland Clinic

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Hypertension, Postpartum Preeclampsia

About this study

To determine if nifedipine and enalapril will have better blood pressure control in the postpartum setting compared to nifedipine and labetalol.

Interventions

Drug: Nifedipine and Enalapril — Nifedipine 60mg by mouth every twelve hours plus Enalapril 5mg by mouth every twelve hours
Drug: Nifedipine and Labetalol — Nifedipine 60mg by mouth every twelve hours plus Labetalol 200mg by mouth every twelve hours

Primary outcomes

Composite postpartum hypertension treatment failure within 6 weeks postpartum (6-weeks postpartum)

Eligibility information

Inclusion Criteria: * Postpartum women aged 18 years or older * Clinical diagnosis of hypertensive disorder in pregnancy (gestational hypertension, chronic hypertension, preeclampsia with or without severe features) * Taking Nifedipine 60 mg every 12 hours for blood pressure control * Persistently elevated blood pressure at/above 140/90 mmHg in a 24-hour time period or have one or more severe range blood pressure at/above 160/110 mmHg requiring a second antihypertensive medication * English speaking Exclusion Criteria: * Taking ≥2 antihypertensive agents during pregnancy * Heart block * Heart rate \<60 or \>120 beats per minute * Heart failure * Creatinine \>1.5 mg/dL * Renal artery stenosis * Active connective tissue disease * Cerebrovascular accident * Failed treatment or contraindications to nifedipine, enalapril or labetalol

Study locations

Cleveland Clinic, Cleveland, Ohio 44195 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.